Quantcast

Latest Rigel Stories

2010-03-05 06:30:00

SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Cowen and Company 30th Annual Health Care Conference in Boston, Massachusetts on Tuesday, March 9th at 3:45 p.m. EST. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website...

2010-03-02 06:00:00

SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2009. For the fourth quarter of 2009, Rigel reported a net loss of $25.1 million, or $0.48 per share, compared to a net loss of $33.4 million, or $0.91 per share, in the fourth quarter of 2008. Weighted average shares outstanding for the fourth quarters of 2009 and 2008 were 51.8 million and 36.6...

2010-02-16 01:01:00

SOUTH SAN FRANCISCO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its senior management team will host a conference call, and simultaneous audio webcast, today at 8:30 a.m. EST (5:30 a.m. PST) to discuss its partnership with AstraZeneca for Rigel's late-stage investigational product, fostamatinib disodium (R788), for the treatment of rheumatoid arthritis and additional indications. Conference Call and Webcast Information To access the...

2010-02-16 01:00:00

SOUTH SAN FRANCISCO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- AstraZeneca and Rigel Pharmaceuticals (Nasdaq: RIGL) today announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications. Fostamatinib disodium, which has completed a comprehensive phase 2 program, is the furthest developed oral Spleen Tyrosine Kinase (Syk)...

2010-02-05 06:30:00

SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 12th Annual BIO CEO & Investor Conference in New York City on Monday, February 8th at 10:00 a.m. EST. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several...

2009-12-23 06:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has received a milestone payment from Daiichi Sankyo Co., Ltd. as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which are intrinsic to cancer cell growth and proliferation. The compound, as yet unnamed, targets cell division. "We believe that ubiquitin ligases represent a promising area of medical...

2009-11-03 06:00:00

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2009. For the third quarter of 2009, Rigel reported a net loss of $26.7 million, or $0.70 per share, compared to a net loss of $37.7 million, or $1.03 per share, in the third quarter of 2008. Weighted average shares outstanding for the third quarters of 2009 and 2008 were 38.1 million and 36.6...

2009-10-16 06:30:00

SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will webcast its analyst briefing on October 20, 2009 from 4:00-5:00pm EDT in conjunction with the 73rd Annual Scientific Meeting of the American College of Rheumatology (ACR). Members of Rigel's senior management team along with the principal investigators for the recently completed Phase 2b clinical trials (TASKi2 and TASKi3) will provide an update on the...

2009-09-17 08:19:00

SOUTH SAN FRANCISCO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a price to the public of $7.25 per share. All of the shares are being offered by Rigel. The underwriters have an option to purchase up to an additional 1,950,000 shares to cover over-allotments, if any. The offering is expected to close on September 22, 2009, subject to the...

2009-09-16 15:00:00

SOUTH SAN FRANCISCO, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it is offering to sell, subject to market and other conditions, 6,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. It is currently anticipated that the underwriters will be granted an over-allotment option for an additional 900,000 shares. Credit Suisse Securities (USA) LLC will be acting...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related